Aspira Womens Health (FRA:CUL) Effective Interest Rate on Debt % : 0.79% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Aspira Womens Health's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was €0.02 Mil. Aspira Womens Health's average total debt for the quarter that ended in Mar. 2024 was €2.54 Mil. Therefore, Aspira Womens Health's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 0.79%.

Aspira Womens Health Effective Interest Rate on Debt % Historical Data

The historical data trend for Aspira Womens Health's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Effective Interest Rate on Debt % Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

1.07

Aspira Womens Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	-	-	0.79

Competitive Comparison of Aspira Womens Health's Effective Interest Rate on Debt %

For the Diagnostics & Research subindustry, Aspira Womens Health's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's Effective Interest Rate on Debt % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Effective Interest Rate on Debt % falls into.

Aspira Womens Health Effective Interest Rate on Debt % Calculation

Aspira Womens Health's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * 0	/	( (3.616	+	2.615)	/ 2 )
=	-1 * 0	/	3.1155
=	0.00 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	2.442	+	1.174
=	3.616

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.703	+	0.912
=	2.615

Aspira Womens Health's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2023 )	+	Total Debt (Q: Mar. 2024 ))	/ count )
=	-1 * -0.02	/	( (2.615	+	2.472)	/ 2 )
=	-1 * -0.02	/	2.5435
=	0.79 %

where

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.703	+	0.912
=	2.615

	Total Debt (Q: Mar. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	1.687	+	0.785
=	2.472

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Aspira Womens Health (FRA:CUL) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Aspira Womens Health Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (FRA:CUL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

AWH:USA

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines